Dr. Philippe Lefrançois

Dermatologist, Montréal, QC

Assistant Professor - McGill University Departments of Medicine, Pharmacology & Therapeutics, and of Surgery.

Dr. Lefrançois is the Director of Research in the Division of Dermatology at McGill University. He is an Assistant Professor of Medicine, of Pharmacology & Therapeutics, and of Surgery. He is a full-time staff dermatologist at the Jewish General Hospital where he is actively involved in multidisciplinary skin cancer clinics and tumor boards. He is an investigator at the Lady Davis Institute where he established a broad skin cancer biobank and a skin cancer translational genomics laboratory. He leads the Terry Fox Research Institute – Marathon of Hope Cancer Centre Network initiatives on BCC and SCC. He is a member of the Réseau Recherche Cancer – Québec, and Québec Cancer Consortium. He co-chairs SkIN Canada’s Translational Research Committee. His research program is supported by the JGH Foundation, LDI, TFRI-MOHCCN, FRQS, Cancer Research Society, Canadian Dermatology Foundation/CIHR, Canadian Foundation for Innovation, Montreal Dermatology Research Institute, and CQDM. His translational activities include collaborations with biotechs to bring novel cancer therapeutics and diagnostics to pre-clinical and phase I studies. Dr. Lefrançois holds a Ph.D. from Yale University, and a M.D. from Université de Montréal. He completed his dermatology residency at McGill. His work on skin cancers has been recognized by the CDA and the AAD.

2:40 PM - 3:10 PM

FRI Apr 19

Heads Up! A Topline Review of 52-Week Tildrakizumab Phase 3 Clinical Data in Scalp Psoriasis

Long-term data from Phase 3 clinical trials prospectively evaluating currently available biologics in the treatment of scalp psoriasis are limited. In this session, 52-week Phase 3 trial data for tildrakizumab, assessing efficacy and patient-reported outcomes in the treatment of moderate-to-severe psoriasis of the scalp, will be presented. To demonstrate how the trial data can translate into the real-world, a patient case will be shared. The session will conclude with an opportunity for the audience to pose questions.

Learning Objectives:
After attending this program, attendees will be able to:

  1. Recognize current unmet needs and challenges in the management of scalp psoriasis
  2. Apply phase 3 clinical trial data of IL-23 inhibitors in the treatment of scalp psoriasis to clinical practice
  3. Identify patients with scalp psoriasis for whom IL-23 inhibitor therapy is appropriate